U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
MENLO PARK, Calif., Oct. 26, 2016 -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2016, on Thursday, November 3, 2016, after the market close. Geron’s management will also host a conference call for analysts and investors on Thursday, November 3, 2016, at 4:30 p.m. Eastern Time to discuss the company’s third quarter results and recent events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 6488635. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://edge.media-server.com/m/p/ci36i65z. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through December 4, 2016.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
